Automating Endocrinology Prior Authorizations with Cognizant TriZetto

For endocrinology practices leveraging Cognizant TriZetto, Klivira delivers intelligent automation to streamline prior authorization processes, reducing manual burden and accelerating patient access to critical therapies.

Endocrinology prior authorizations are complex, driven by high-volume categories like GLP-1 agonists, CGMs, and insulin pumps, each with nuanced payer criteria. Integrating these workflows with a clearinghouse and payer platform like Cognizant TriZetto requires a strategic approach to ensure efficiency and compliance. Klivira provides the necessary automation layer to navigate these challenges.

The Endocrinology Prior Authorization Landscape with Cognizant TriZetto

Endocrinology practices face a significant prior authorization burden, particularly for high-cost medications and devices critical for managing conditions like diabetes. For organizations leveraging Cognizant TriZetto as their clearinghouse and payer platform, integrating these complex PA workflows is essential. Klivira enhances this ecosystem by automating the data assembly and submission process, ensuring that critical patient information flows efficiently from EMRs through TriZetto to payers.

Key Prior Authorization Triggers in Endocrinology

GLP-1 receptor agonists (e.g., Ozempic, Mounjaro, Zepbound)
Continuous Glucose Monitoring (CGM) devices
Insulin pumps and tubeless systems
Growth hormone therapy
SGLT2 inhibitors
Complex insulin regimens

Navigating Payer Criteria and Documentation Requirements

Endocrinology PAs demand meticulous documentation adherence to guidelines such as the ADA Standards of Care and AACE Clinical Practice Guidelines. Klivira's platform is engineered to identify and surface the specific data points required for therapies like GLP-1s (A1c, BMI, prior trials), CGMs (diabetes type, insulin-requiring status), and insulin pumps (MDI trials, patient training). This ensures that prior authorization requests submitted via channels including Cognizant TriZetto are complete and accurate.

Addressing Common Denial Factors in Endocrinology

Frequent denial reasons in endocrinology include payer-specific coverage gaps for obesity indications, step therapy non-compliance for GLP-1 RAs, and insufficient justification for CGM use in non-insulin-requiring T2D patients. Klivira proactively flags these potential issues, guiding staff to provide the necessary documentation or explore alternative pathways before submission, thereby reducing rework and accelerating approvals through platforms like Cognizant TriZetto.

Klivira's Automation Layer for TriZetto Users in Endocrinology

Klivira provides a robust automation layer designed to complement the existing infrastructure of endocrinology practices utilizing Cognizant TriZetto. Our solution streamlines the high-volume PA requests for GLP-1s, manages re-authorization cycles for CGMs and insulin pumps, and intelligently routes requests based on payer-specific obesity benefit status and biosimilar substitution requirements. This integration ensures a cohesive workflow from clinical order to payer decision.

Optimizing EMR and Payer Connectivity for Endocrinology

Effective prior authorization in endocrinology relies on seamless data exchange between EMRs and payer systems. Klivira integrates directly with leading EMRs via SMART on FHIR, extracting necessary clinical data. For submissions, Klivira leverages channels like X12 278 transactions, ePA portals, and direct payer portals, ensuring that requests are submitted through the most efficient route, including via clearinghouses such as Cognizant TriZetto, minimizing manual intervention.

Frequently asked questions

How does Klivira manage the high volume of GLP-1 prior authorizations for endocrinology practices?

Klivira automates the data extraction and submission for GLP-1 agonists, intelligently routing requests based on indication (T2D vs. obesity) and payer-specific criteria. This includes identifying required documentation like A1c, BMI, and prior medication trials, streamlining the process for practices using Cognizant TriZetto.

Can Klivira automate re-authorizations for continuous glucose monitors (CGMs) and insulin pumps?

Yes, Klivira supports the automation of re-authorization cycles for CGMs and insulin pumps. Our system tracks re-authorization dates and prompts for necessary adherence documentation, ensuring timely submissions and continuous patient access to these critical diabetes management devices via integrated channels like Cognizant TriZetto.

How does Klivira integrate with our existing EMR and Cognizant TriZetto for endocrinology workflows?

Klivira offers deep integration with major EMR systems using standards like SMART on FHIR, allowing for automated extraction of clinical data. For prior authorization submission, Klivira connects with clearinghouses like Cognizant TriZetto, facilitating X12 278 transactions and optimizing data flow from your EMR to payers.

What role do clinical guidelines like ADA Standards of Care play in Klivira's PA automation for endocrinology?

Klivira's automation logic is informed by leading clinical guidelines such as the ADA Standards of Care and AACE Clinical Practice Guidelines. This ensures that the system proactively identifies and prompts for documentation aligned with payer medical policies, improving the completeness and accuracy of prior authorization requests for endocrine therapies.

How does Klivira help address common denial reasons for endocrinology prior authorizations?

Klivira's platform is designed to flag common denial reasons, such as missing step therapy documentation for GLP-1s or insufficient criteria for CGM coverage. By identifying these issues pre-submission, Klivira helps practices using Cognizant TriZetto to proactively address gaps, reducing denials and appeals.